Treace Medical (TMCI) announced that Guy Guglielmino joined the company as chief commercial officer. In this new position, Guglielmino will lead Treace’s commercial efforts and play a role in driving the company’s next phase of innovation, strategic product commercialization, and growth. Most recently, Guglielmino was president, Recovery Sciences at Enovis (ENOV).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMCI:
- Treace Medical assumed with an Equal Weight at Morgan Stanley
- Treace Medical price target raised to $8 from $7 at Stifel
- Treace Medical Concepts Reports Strong Q3 2024 Growth
- Closing Bell Movers: Exact Sciences falls 30% after results, guidance cut
- Treace Medical reports Q3 EPS (25c), consensus (27c)